MX2013004137A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2013004137A
MX2013004137A MX2013004137A MX2013004137A MX2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A MX 2013004137 A MX2013004137 A MX 2013004137A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
indacaterol
ciclesonide
beta2
formoterol
Prior art date
Application number
MX2013004137A
Other languages
English (en)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MX2013004137A publication Critical patent/MX2013004137A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica que comprende un agonista beta2 seleccionado de indacaterol y formoterol en combinación con un corticosteroide seleccionado de fluticasona y ciclesonida, y, opcionalmente, uno o más excipientes farmacéuticamente aceptables.
MX2013004137A 2010-10-12 2011-07-25 Composicion farmaceutica. MX2013004137A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN2847MU2010 2010-10-12
IN69MU2011 2011-01-10
IN106MU2011 2011-01-12
IN135MU2011 2011-01-14
IN143MU2011 2011-01-17
PCT/GB2011/001115 WO2012049444A1 (en) 2010-10-12 2011-07-25 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2013004137A true MX2013004137A (es) 2013-07-29

Family

ID=44651863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004137A MX2013004137A (es) 2010-10-12 2011-07-25 Composicion farmaceutica.

Country Status (12)

Country Link
US (1) US10179139B2 (es)
EP (1) EP2627325A1 (es)
JP (2) JP2013542940A (es)
KR (2) KR20140025308A (es)
CN (2) CN103269694A (es)
AU (1) AU2011315315B2 (es)
BR (1) BR112013008974A2 (es)
CA (1) CA2814445A1 (es)
MX (1) MX2013004137A (es)
NZ (1) NZ609358A (es)
RU (1) RU2642624C2 (es)
WO (1) WO2012049444A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ609358A (en) 2010-10-12 2015-04-24 Cipla Ltd Pharmaceutical compositions for inhalation
CN103784420A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 马来酸茚达特罗液体制剂及其制备方法
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
BR112017023351B1 (pt) * 2015-05-01 2023-11-28 Board Of Regents, The University Of Texas System Composição farmacêutica e uso da composição farmacêutica
ES2826562T3 (es) * 2015-05-18 2021-05-18 Glenmark Specialty Sa Solución para inhalación de tiotropio por nebulizador
UA124240C2 (uk) * 2016-09-19 2021-08-11 Мехікем Флуор С.А. Де С.В. Фармацевтична композиція
GB2554090A (en) * 2016-09-19 2018-03-28 Mexichem Fluor Sa De Cv Pharmaceutical compound
JP6781831B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
TR201712424A2 (tr) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
JPWO2019146188A1 (ja) 2018-01-24 2021-01-07 ソニー株式会社 情報処理装置および情報処理方法
EA202092976A1 (ru) * 2018-06-04 2021-03-16 Люпин Инк. Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением
WO2020105012A1 (en) * 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
WO2020141472A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
WO2021068961A1 (zh) * 2019-10-11 2021-04-15 四川海思科制药有限公司 一种吸入溶液药物组合物及其制备方法
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CA3179014A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
WO2024097413A1 (en) * 2022-11-03 2024-05-10 Dana-Farber Cancer Institute, Inc. Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US5879715A (en) 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
JP4287613B2 (ja) 2000-04-28 2009-07-01 田辺三菱製薬株式会社 マイクロスフェアの製法
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
ATE396716T1 (de) * 2002-02-04 2008-06-15 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
JP2006527237A (ja) 2003-06-13 2006-11-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ホルモテロールと及びシクレソニドの組合せ物
SE527200C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
US20050258288A1 (en) 2003-11-26 2005-11-24 E. I. Du Pont De Nemours And Company High pressure media milling system and process of forming particles
US20060008498A1 (en) 2004-07-12 2006-01-12 Chen Tzer-Fen D Nano-particle production
DE102004056578A1 (de) 2004-11-23 2006-05-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Formoterol und ein Steroid
JPWO2006073154A1 (ja) 2005-01-07 2008-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物及びその製造方法
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CA2824075C (en) * 2005-12-21 2015-04-28 Joachim Maus Combination of r, r-glycopyrrolate, formoterol, and a glucocorticoid for the treatment of inflammatory diseases
WO2008064357A2 (en) 2006-11-22 2008-05-29 University Of Florida Research Foundation, Inc. Nanoparticles for protection of cells from oxidative stress
PE20081788A1 (es) 2007-02-19 2008-12-18 Cipla Ltd Combinaciones farmaceuticas
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
JP5109515B2 (ja) 2007-07-17 2012-12-26 株式会社ジェイテクト 摺動式トリポード形等速ジョイント
BRPI0816255A2 (pt) * 2007-09-12 2015-03-17 Glaxo Group Ltd Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
DE102007054885A1 (de) 2007-11-15 2009-05-20 Evonik Degussa Gmbh Verfahren zur Fraktionierung oxidischer Nanopartikel durch Querstrom-Membranfiltration
FR2929136B1 (fr) 2008-03-25 2011-11-11 Sprainnov Procede et tete de pulverisation, procede et tour associes pour fabriquer un produit pulverulent
MX2011000405A (es) * 2008-07-18 2011-03-04 Prosonix Ltd Proceso para mejorar la cristalinidad.
CN101474191B (zh) * 2009-01-21 2011-03-23 李虎山 一种治疗哮喘和慢性阻塞性肺病的药物组合物
US8668901B2 (en) * 2009-02-04 2014-03-11 Activaero Gmbh Research & Development Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
EP2221048A1 (en) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
UA110773C2 (uk) 2009-04-24 2016-02-25 Айсьютіка Пті Лтд Спосіб одержання порошків, що містять нано- і мікрочастинки
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
NZ609358A (en) 2010-10-12 2015-04-24 Cipla Ltd Pharmaceutical compositions for inhalation

Also Published As

Publication number Publication date
RU2013119938A (ru) 2014-11-20
AU2011315315A1 (en) 2013-05-09
RU2642624C2 (ru) 2018-01-25
KR20180028563A (ko) 2018-03-16
EP2627325A1 (en) 2013-08-21
KR20140025308A (ko) 2014-03-04
WO2012049444A1 (en) 2012-04-19
NZ609358A (en) 2015-04-24
JP2017039746A (ja) 2017-02-23
BR112013008974A2 (pt) 2023-12-19
AU2011315315B2 (en) 2016-08-18
US20140147393A1 (en) 2014-05-29
CN103269694A (zh) 2013-08-28
CN107998109A (zh) 2018-05-08
US10179139B2 (en) 2019-01-15
CA2814445A1 (en) 2012-04-19
JP2013542940A (ja) 2013-11-28

Similar Documents

Publication Publication Date Title
MX2013004137A (es) Composicion farmaceutica.
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
HK1223309A1 (zh) 用於吸入器的劑量計數器、吸入器及其軸
MX2013000642A (es) Composiciones farmaceuticas.
IL243303A (en) Alpha radiation-emitting complexes and pharmaceuticals containing them
PT2688572T (pt) Composição farmacêutica com um inibidor de hdac e um esteroide e sua utilização
EP2950822A4 (en) PHARMACEUTICAL PREPARATION FOR THE PROTECTION OF WOUNDS BY HEMOSTASIS OR TO PREVENT ADHESION IN THE STOMACH DARM TRACT
ZA201509290B (en) Dose counters for inhalers,inhalers and shafts thereof
EP2560614A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION
IL221820B (en) Use of a compound selected from 21-methoxy-17α-acetoxy-11β-(4 n,n- dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and 17α-acetoxy-11β-(4 n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione in the manufacture of a medicament
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
ZA201508249B (en) A pharmaceutical composition containing budesonide and formoterol.
WO2010150098A3 (en) Use of quingolide in the treatment of endometriosis, pain and cancer
HK1170431A1 (en) Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome
IN2013MU03370A (es)
IN2013MU02015A (es)
张小春 Incongruity and Resolution of Verbal Humor
聂文凯 Intertextuality and Translation
AP2011006026A0 (en) Medicinal and herbal composition.